help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snyder, P. J.
Right arrow Articles by Lawrence, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snyder, P. J.
Right arrow Articles by Lawrence, D. A.

Journal of Clinical Endocrinology & Metabolism, Vol 51, 1335-1339, Copyright © 1980 by Endocrine Society

ARTICLES

Treatment of male hypogonadism with testosterone enanthate

PJ Snyder and DA Lawrence

To determine the relative efficacy of several dosage regimens of testosterone enanthate in the treatment of male hypogonadism, we treated men who had primary hypogonadism with the following dosage regimens: 100 mg once a week, 200 mg every 2 weeks, 300 mg every 3 weeks, and 400 mg every 4 weeks, each for 12--16 weeks. Twenty-three men completed 37 dosage regimens. The 100-, 200-, and 300-mg dosages all suppressed the initially elevated serum LH concentrations to normal, but the 400-mg dosage did not. The 100- and 200-mg regimens suppressed the initially elevated serum FSH concentrations to normal, and the 300-mg regimen almost did not so. All four regimens produced serum testosterone concentrations that fluctuated largely within the normal range, the average concentration between doses was highest with 100 mg and lowest with 400 mg. The regimens of 200 mg every 2 weeks and 300 mg every 3 weeks appeared to be the most effective of those tested in terms of suppression of the serum LH concentration to normal and infrequency of administration. The close parallel of the FSH response to that of LH suggests that testosterone is the major physiological inhibitor of FSH as well as of LH.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Mueller, F. Kiesewetter, H. Binder, M. W. Beckmann, and R. Dittrich
Long-Term Administration of Testosterone Undecanoate Every 3 Months for Testosterone Supplementation in Female-to-Male Transsexuals
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3470 - 3475.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. Muniyappa, J. D. Sorkin, J. D. Veldhuis, S. M. Harman, T. Munzer, S. Bhasin, and M. R. Blackman
Long-term testosterone supplementation augments overnight growth hormone secretion in healthy older men
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E769 - E775.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
A. Qoubaitary, C. Meriggiola, C. M. Ng, L. Lumbreras, S. Cerpolini, G. Pelusi, P. D. Christensen, L. Hull, R. S. Swerdloff, and C. Wang
Pharmacokinetics of Testosterone Undecanoate Injected Alone or in Combination With Norethisterone Enanthate in Healthy Men
J Androl, November 1, 2006; 27(6): 853 - 867.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. A. Perera, D. Yin, D. Wu, K. K. Chan, D. D. Miller, and J. Dalton
In Vivo Metabolism and Final Disposition of a Novel Nonsteroidal Androgen in Rats and Dogs
Drug Metab. Dispos., October 1, 2006; 34(10): 1713 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Kim, D. Wu, D. J. Hwang, D. D. Miller, and J. T. Dalton
The Para Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides Is a Major Structural Determinant of in Vivo Disposition and Activity of Selective Androgen Receptor Modulators
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 230 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Aminorroaya, S. Kelleher, A. J Conway, L. P Ly, and D. J Handelsman
Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men
Eur. J. Endocrinol., June 1, 2005; 152(6): 881 - 886.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Wang, R. Swerdloff, M. Kipnes, A. M. Matsumoto, A. S. Dobs, G. Cunningham, L. Katznelson, T. J. Weber, T. C. Friedman, P. Snyder, et al.
New Testosterone Buccal System (Striant) Delivers Physiological Testosterone Levels: Pharmacokinetics Study in Hypogonadal Men
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3821 - 3829.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Korbonits, M. Slawik, D. Cullen, R. J. Ross, G. Stalla, H. Schneider, M. Reincke, P. M. Bouloux, and A. B. Grossman
A Comparison of a Novel Testosterone Bioadhesive Buccal System, Striant, with a Testosterone Adhesive Patch in Hypogonadal Males
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2039 - 2043.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. W. F. T. Toorians, S. Kelleher, L. J. Gooren, M. Jimenez, and D. J. Handelsman
Estimating the Contribution of the Prostate to Blood Dihydrotestosterone
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5207 - 5211.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Machluf, A. Orsola, S. Boorjian, R. Kershen, and A. Atala
Microencapsulation of Leydig Cells: A System for Testosterone Supplementation
Endocrinology, November 1, 2003; 144(11): 4975 - 4979.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
Z.'e. Hochberg, K. Pacak, and G. P. Chrousos
Endocrine Withdrawal Syndromes
Endocr. Rev., August 1, 2003; 24(4): 523 - 538.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Moore, A. Wisniewski, and A. Dobs
Endocrine Treatment of Transsexual People: A Review of Treatment Regimens, Outcomes, and Adverse Effects
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3467 - 3473.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. J. Woodhouse, S. Reisz-Porszasz, M. Javanbakht, T. W. Storer, M. Lee, H. Zerounian, and S. Bhasin
Development of models to predict anabolic response to testosterone administration in healthy young men
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1009 - E1017.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. L. Herbst, B. D. Anawalt, J. K. Amory, A. M. Matsumoto, and W. J. Bremner
The Male Contraceptive Regimen of Testosterone and Levonorgestrel Significantly Increases Lean Mass in Healthy Young Men in 4 Weeks, but Attenuates a Decrease in Fat Mass Induced by Testosterone Alone
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1167 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Yin, H. Xu, Y. He, L. I. Kirkovsky, D. D. Miller, and J. T. Dalton
Pharmacology, Pharmacokinetics, and Metabolism of Acetothiolutamide, a Novel Nonsteroidal Agonist for the Androgen Receptor
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1323 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Yin, W. Gao, J. D. Kearbey, H. Xu, K. Chung, Y. He, C. A. Marhefka, K. A. Veverka, D. D. Miller, and J. T. Dalton
Pharmacodynamics of Selective Androgen Receptor Modulators
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1334 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
A. M. Matsumoto
Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men
J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99.
[Full Text]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Bhasin, L. Woodhouse, R. Casaburi, A. B. Singh, D. Bhasin, N. Berman, X. Chen, K. E. Yarasheski, L. Magliano, C. Dzekov, et al.
Testosterone dose-response relationships in healthy young men
Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1172 - E1181.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. M. Hair, K. Kitteridge, D. B. O'Connor, and F. C. W. Wu
A Novel Male Contraceptive Pill-Patch Combination: Oral Desogestrel and Transdermal Testosterone in the Suppression of Spermatogenesis in Normal Men
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5201 - 5209.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. A. Schnorr, M. J. Bray, and J. D. Veldhuis
Aromatization Mediates Testosterone's Short-Term Feedback Restraint of 24-Hour Endogenously Driven and Acute Exogenous Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone and Follicle-Stimulating Hormone Secretion in Young Men
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2600 - 2606.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. J. Snyder, H. Peachey, J. A. Berlin, P. Hannoush, G. Haddad, A. Dlewati, J. Santanna, L. Loh, D. A. Lenrow, J. H. Holmes, et al.
Effects of Testosterone Replacement in Hypogonadal Men
J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2670 - 2677.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
D. Vanderschueren, L. Vandenput, S. Boonen, E. Van Herck, J. V. Swinnen, and R. Bouillon
An Aged Rat Model of Partial Androgen Deficiency: Prevention of Both Loss of Bone and Lean Body Mass by Low-Dose Androgen Replacement
Endocrinology, May 1, 2000; 141(5): 1642 - 1647.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. S. Dobs, A. W. Meikle, S. Arver, S. W. Sanders, K. E. Caramelli, and N. A. Mazer
Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3469 - 3478.
[Abstract] [Full Text] [PDF]

Home page
 Arch Fam MedHome page
S. J. Winters
Current Status of Testosterone Replacement Therapy in Men
Arch Fam Med, May 1, 1999; 8(3): 257 - 263.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. E. Cummings, N. Kumar, C. W. Bardin, K. Sundaram, and W. J. Bremner
Prostate-Sparing Effects in Primates of the Potent Androgen 7{alpha}-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception
J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4212 - 4219.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhasin, T. W. Storer, N. Asbel-Sethi, A. Kilbourne, R. Hays, I. Sinha-Hikim, R. Shen, S. Arver, and G. Beall
Effects of Testosterone Replacement with a Nongenital, Transdermal System, Androderm, in Human Immunodeficiency Virus-Infected Men with Low Testosterone Levels
J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3155 - 3162.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhasin and W. J. Bremner
Emerging Issues in Androgen Replacement Therapy
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 3 - 8.
[Full Text] [PDF]

Home page
 NEJMHome page
C. W. Bardin
The Anabolic Action of Testosterone
N. Engl. J. Med., July 4, 1996; 335(1): 52 - 53.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society